Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...

The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...

We welcome two special guests, Dr. Stacy Lindborg, and Dr. Premal Thaker, to discuss the results of the OVATION 2 Study and ...

The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.

The FDA has approved the Altius® System, an innovative device for managing chronic pain in lower limb amputees. Utilizing direct electrical nerve stimulation, the device proved effective in reducing ...

The application for nipocalimab was submitted to the FDA for the treatment of generalized myasthenia gravis (gMG), following promising results from the Phase 3 Vivacity-MG3 study. This ...

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we will explore the ...

The FDA has approved Illumina's TruSight Oncology Comprehensive test as a companion diagnostic for two cancer indications. This biomarker test profiles over 500 genes in solid tumors, aiding in the ...

The first human trial of BNT116, an mRNA-based lung cancer vaccine, has started, and the first patient received the treatment at UCLH. Developed by BioNTech, the vaccine targets non-small cell lung ...

The next-generation weight loss therapeutic, nimacimab, has entered the Phase 2 CBeyond clinical trial. The study aims to determine the safety of nimacimab, focusing on sustainable weight loss and ...